NCT06409052

Brief Summary

To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for all trials

Timeline
3mo left

Started Jun 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
Jun 2024Aug 2026

First Submitted

Initial submission to the registry

May 7, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 10, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

June 25, 2024

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 3, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 3, 2026

Last Updated

January 14, 2026

Status Verified

January 1, 2026

Enrollment Period

2.1 years

First QC Date

May 7, 2024

Last Update Submit

January 13, 2026

Conditions

Endometrial Cancer

Outcome Measures

Primary Outcomes (1)

  • Patient education

    To build a patient tool for educating and empowering women to make informed decisions about endometrial cancer prevention strategies.

    Through study completion; an average of 1 year.

Interventions

Qualitative interviewsBEHAVIORAL

Interviews will be conducted for approximately 45-60 minutes

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women with or without a diagnosis of endometrial cancer or endometrial hyperplasia

You may qualify if:

  • Women who present to MD Anderson Cancer Center including MDA Houston Area Locations with a diagnosis of endometrial cancer
  • Women who present to MD Anderson Cancer Center including MDA Houston Area Locations with a diagnosis of abnormal uterine bleeding or endometrial hyperplasia
  • Women without a diagnosis of endometrial cancer or endometrial hyperplasia
  • Women must be at least 18 years or age
  • Women must be able to read, write, and speak English
  • Women must be willing and able to provide written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Larissa Meyer, MD

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Larissa Meyer, MD

CONTACT

(713) 745-0973lmeyer@mdanderson.org

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 7, 2024

First Posted

May 10, 2024

Study Start

June 25, 2024

Primary Completion (Estimated)

August 3, 2026

Study Completion (Estimated)

August 3, 2026

Last Updated

January 14, 2026

Record last verified: 2026-01

Locations

US(1)